Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100862 · ClinicalTrials.gov registry record · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
A Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma, sponsored by BeiGene.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 780
- Enrollment target
- 20
- Study locations
NCT05100862 is a Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma that is actively recruiting participants, run by BeiGene. The registered enrollment target is 780 participants, above the 87-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (797% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05100862, a Phase 3 study of Marginal Zone Lymphoma and Relapsed/Refractory Follicular Lymphoma, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 780 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG Lenalidomide
Study Locations (20)
California
- Ucsf Fresno University of California San Francisco Fresno - Fresno
- Kaiser Permanente Southern California - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- Los Angeles Cancer Network - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- UCLA Hematologyoncology - Los Angeles
- Scripps Health - San Diego
- Sharp Healthcare Sharp Memorial Hospital - San Diego
Florida
- Baptist Md Anderson Cancer Center - Jacksonville
- Ascension Sacred Heart - Pensacola
Kansas
- Cotton Oneil Cancer Center - Topeka
- Cancer Center of Kansas - Wichita
Maryland
- Luminis Health Anne Arundel Medical Center - Annapolis
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Georgia
- Northwest Georgia Oncology Centers Marietta - Marietta
Illinois
- Cancer Care Specialists of Illinois - Decatur
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Iowa
- Mission Cancer and Blood - Waukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2030-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05100862
The ClinicalTrials.gov registry entry for NCT05100862 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 780 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (797% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT05100862 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05100862 about?
NCT05100862 is a clinical study titled "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma". The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accord...
What is the current status of trial NCT05100862?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 780 participants. The study started on 2022-03-10. Estimated completion is 2030-06.
What conditions does trial NCT05100862 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma, Relapsed/Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT05100862?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT05100862?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05100862 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
Explore more on PlainTrial
Marginal Zone Lymphoma
All registered trials for this condition
Relapsed/Refractory Follicular Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.